China biotechnology and healthcare industry under the 15th Five-Year Plan: China biotech’s 15th Five-Year Plan targets appear achievable, but funding and execution are the real tests

Overview

This report assesses how China’s 15th Five-Year Plan biotechnology objectives compare with the current innovation pipeline, domestic healthcare-financing capacity and industrial infrastructure. Morgan Stanley sees the global innovation and blockbuster goals as broadly supported by existing momentum, while viewing reimbursement funding, commercialization and specialized manufacturing investment as the critical next-stage drivers.

Core views

Morgan Stanley argues that China is already close to, or above, the run-rate needed to meet MIIT’s global biotechnology milestones by 2030. PharmCube places China’s share of first-in-class innovation at 24%, close to MIIT’s 25% target, while BCG reports a 34% share of new potential first-in-class clinical entries in 2025 and IQVIA reports a 30% share of global trial starts in 2024. The report notes that these measures are not identical: PharmCube’s asset-level definition most closely resembles MIIT’s stated Phase I-through-approval perimeter, whereas other datasets include preclinical assets, apply global-development-leadership criteria or count trial starts. Morgan Stanley therefore views the target as attainable, but stresses that approval conversion and commercial uptake—not simply pipeline creation—will determine the revenue outcome. The five-product US$1bn objective is also described as visible in the current portfolio. Brukinsa and Carvykti already exceeded US$1bn in annual global sales. Consensus forecasts place tislelizumab, ivonescimab and sac-TMT above US$1bn in 2030, while sonrotoclax is forecast at US$885m in 2030 and US$1.3bn in 2031. Morgan Stanley identifies registration, indication expansion and launch execution as the conditions needed to translate this product set into the target. It maintains its longer-term 2040 forecast that China-originated products will account for 35% of US FDA approvals and generate US$220bn of ex-China revenue. That forecast assumes 32% of China-originated assets reaching Phase III in China enter global Phase III multi-regional trials by 2040. The report’s near-term globalization evidence is mixed but broadly constructive. Funding including licensing upfronts reached US$12.2bn in the first eight months of 2026, or 96% of Morgan Stanley’s US$12.7bn full-year forecast, and eight China new molecular entities entered US Phase III, matching the full-year assumption. By contrast, 409 China NME Phase I initiations annualize below the 691 forecast, and one BLA approval has occurred against four assumed for the year, with two PDUFA decisions outstanding. Morgan Stanley sees approvals, Phase III starts, BLA and supplemental BLA submissions, PDUFA dates, global clinical readouts and retained economics under licensing or co-development as the decisive tests of whether Chinese innovation is globally translatable rather than merely licensable. On domestic demand, Morgan Stanley views MIIT’s goal of at least 20% annual innovative-drug growth as consistent with its own 21% CAGR forecast for a roughly US$200bn China innovative-drug market by 2030. Its base case assumes innovative medicines rise from 29% of drug spending in 2024 to 53% in 2030, while generic drugs grow only 2%. The report argues that this implies continued pricing and portfolio pressure on established therapies as reimbursement is reallocated toward innovative products. It also notes that pharmaceutical industrial revenue of Rmb2.956tn in 2025 would need only about 3.4% annual growth to reach the Rmb3.5tn 2030 industrial objective, but this industrial measure includes exports, APIs and intermediate manufacturing and therefore should not be equated directly with the domestic drug market. Funding is presented as the binding constraint on domestic growth. Morgan Stanley’s scenario assumes nominal GDP growth of 3.5% in 2026-30, healthcare spending reaching 9.3% of GDP by 2030 from 6.7% in 2021, and total healthcare expenditure rising from Rmb9.34tn in 2025 to Rmb15.3tn in 2030, a 10.4% CAGR. It expects social, commercial and corporate sources to provide 54% of spending, or Rmb8.26tn, versus Rmb4.46tn in 2025, requiring roughly 13.1% annual growth. Government spending still rises to Rmb3.21tn but falls to a 21% share, while personal spending falls to a 25% share. Ageing demographics constrain social insurance, and commercial insurance remains small: 2025 health-insurance premiums were Rmb997.3bn, up about 2%. The new commercial innovative-drug catalogue covers 19 medicines, but its impact depends on inclusion in insurance products, eligibility, benefit limits and claims payment. The report also identifies biotechnology/pharmaceutical parks as a multi-year manufacturing-investment theme. MIIT’s target of 20 parks at Rmb100bn scale implies at least Rmb2tn of combined activity. Morgan Stanley’s screen finds seven clusters already around or above the threshold and estimates an indicative Rmb720bn expansion gap across the top 20 parks. Applying an average investment-to-output ratio of about 0.19x from three disclosed projects produces an estimated Rmb140bn of project investment, within a Rmb110bn-Rmb180bn peer range. With utilization at 72.5% in 2025, the report expects incremental capital spending to favor conjugate, peptide and oligonucleotide capacity rather than general-purpose expansion. Equipment orders should be the earliest signal of demand, followed by materials consumption and CDMO service revenue, although outsourced manufacturing demand depends on developers’ project awards and in-house factory expansion could reduce outsourcing.

Analysis framework

Morgan Stanley compares MIIT’s policy targets with current pipeline, clinical-trial, sales and funding data; tests the targets against its existing 2030 and 2040 forecasts; then translates domestic growth and park targets into healthcare-financing requirements and manufacturing-investment estimates. It tracks regulatory conversion, reimbursement access, funding-source growth, utilization and customer orders as implementation indicators.

Methodology notes

• Industry AnalysisSupply-demand framework

  Innovative-drug demand growth and healthcare funding capacity

  The report compares projected drug-market growth with the required expansion and mix of healthcare funding, treating reimbursement and payer capacity as the constraint on sales realization.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Biopharma park expansion transmission

  The report links park construction to earlier equipment orders, then to recurring materials demand and potential CDMO revenue as manufacturing output rises.

• Industry Analysis

  Project investment-to-output sensitivity

  Morgan Stanley estimates park-related investment by applying the average disclosed investment/output ratio from three manufacturing projects to the estimated Rmb720bn expansion gap.

Key data

• China share of first-in-class innovation24%-34%PharmCube reports 24% against MIIT’s 25% 2030 target; BCG reports 34% of 2025 potential-FIC clinical entries.
• China innovative-drug marketc.US$200bn by 2030Morgan Stanley base case assumes a 21% CAGR in 2024-30.
• Innovative medicines share of drug spending29% in 2024 to 53% in 2030Morgan Stanley base-case mix assumption.
• Healthcare expenditureRmb9.34tn in 2025 to Rmb15.3tn in 2030The financing scenario requires 10.4% annual growth.
• Social, commercial and corporate healthcare fundingRmb4.46tn in 2025 to Rmb8.26tn in 2030Required CAGR is about 13.1%; the share rises to 54%.
• China biotech funding in 8M26US$12.2bnIncluding licensing upfronts; equal to 96% of Morgan Stanley’s US$12.7bn full-year forecast.
• Biopharma-park expansion bridgec.Rmb720bn output gap and c.Rmb140bn project investmentThe investment estimate is based on a c.0.19x average investment/output ratio.

Impact & implications

Morgan Stanley sees policy targets as reinforcing its positive China biotech outlook, but argues that the next value-creation stage depends on global regulatory and commercial conversion, broader reimbursement and supplementary-insurance coverage, and specialized manufacturing investment. The report expects established therapies to face greater pricing and mix pressure as spending shifts toward innovation.

Risks

• The domestic innovative-drug growth target may be constrained if social insurance, commercial insurance and corporate funding do not expand sufficiently.
• Global revenue realization depends on approvals, pivotal-trial success, registration, indication expansion and overseas launch execution.
• Commercial insurance may not materially broaden access unless innovative drugs are incorporated into products with adequate eligibility, benefit limits and claims payment.
• Park-investment estimates are sensitive to project output assumptions, the timing of expenditure and the contribution from existing capacity.
• CDMO demand depends on outsourced project awards, while companies expanding in-house factories may internalize production.

What to watch

• US Phase III starts, BLA and supplemental BLA submissions, PDUFA decisions and global clinical readouts for China-originated assets.
• Global approval rates, product-level sales and the share of commercial economics retained through licensing, co-development and direct participation.
• Insurance-fund revenue, benefit expenditure, reimbursed drug volumes and innovative-drug reimbursement access.
• Drug-specific commercial-insurance coverage, reimbursed patient numbers and direct-settlement progress.
• Biopharma equipment order wins, customer commitments, utilization rates and manufacturing-material demand.